Blood: Tumor internal and external markers that affect the effectiveness of Bona Twain anti-treatment in B-ALL patients.

Blinatumomab (Bonatumomab), a dual-specific antibody that targets CD3-T cells and CD19-plus tumor cells, shows different efficacy in B-all.
In order to clearly determine the internal and external source factors of reactive tumors, Zhao et al. studied 44 adult patients (including 2 MRD-positive patients) who were treated with Bonato monoantigen resistance using single-cell sequencing.
55 percent for patients with blood disorders, and higher for Philadelphia chromosome (Ph)-like ALL patients with CRLF2 re-platooning (12/16, 75 percent).
pre-treated samples of the respondents showed intra-tumor transcription characteristics with increased immune response.
multiple mechanisms lead to CD19 expression loss, including CD19 gene mutation, CD19 mutant allegant gene specific expression, low CD19 RNA expression, and CD19 signal complex partner CD81 mutation.
patients with low medial secondary are prone to CD19-negative recurrence due to the loss of non-mutated CD19 alleometan genes that are not whole-body mediated.
the increase in CD19 subtype (CD19 ex2part) expression of exon shear variant 2 during baseline or treatment was associated with treatment failure.
study, both internal and external factors in tumors can affect a patient's response to Bonathumant anti-treatment.
CD19 mutations are common in patients with CD19-negative recurrence during Bona Twain anti-treatment.
detection of CD19 ex2part shear variation represents a new biomarker that predicts the failure of Bonaparte anti-treatment.
.